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Abstract
To shorten the time required to find effec-
tive new drugs, like antivirals, a key parame-
ter to consider is membrane permeability, as a
compound intended for an intracellular target
with poor permeability will have low efficacy.
Here, we present a computational model that
considers both drug characteristics and mem-
brane properties for the rapid assessment of
drugs permeability through the coronavirus en-
velope and various cellular membranes. We an-
alyze 79 drugs that are considered as potential
candidates for the treatment of SARS-CoV-2
and determine their time of permeation in dif-
ferent organelle membranes grouped by viral
baits and mammalian processes. The computa-
tional results are correlated with experimental
data, present in the literature, on bioavailabil-
ity of the drugs, showing a negative correlation
between fast permeation and most promising
drugs. This model represents an important tool
capable of evaluating how permeability affects
the ability of compounds to reach both intended
and unintended intracellular targets in an accu-
rate and rapid way. The method is general and
flexible and can be employed for a variety of
molecules, from small drugs to nanoparticles,
as well to a variety of biological membranes.
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Introduction
The 2020 pandemic has brought the chasm be-
tween the rapid spread of infectious diseases
and the relative slow pace of scientific discovery
to stark reality. This particular event is not the
first, nor it will be the last. Since the turn of
the century three different coronavirus threats
have surfaced and emerging infectious diseases
will continue to be a threat for the foreseeable
future. Current methods for studying betacoro-
naviruses, responsible for the 2020 pandemic,
are technically and time demanding. Viral iso-
lation from field sample is rarely successful and
reverse genetics recovery of recombinant virus
is labor intensive and expensive. Similarly, the
design and testing of new drugs is an extremely
lengthy process. To this end, drug repurposing,
where existing compounds that have already
been tested safe in humans, are redeployed to
combat another disease, has emerged as a crit-
ical strategy. As an example, Remdesivir, one
of the promising COVID-19 drug candidates at
the moment, is a broad-spectrum drug that was
originally targeted toward a number of viruses,
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Figure 1: Flow and data source used in this work.
such as SARS-CoV and MERS-CoV, but also
studied to counter Ebola virus infection.
Multiple characteristics define the potency of
a drug, as well as its side effects. Among
them, bioavailability - the fraction of a com-
pound that reaches the intended target - is
one of the hardest to estimate reliably and
rapidly. Although several factors contribute to
in defining bioavailability, passive permeability
through different biological membranes is a crit-
ical component since independent of the ability
of a drug to bind to its target, the inability to
reach the intended target often translates into
poor in vivo efficacy and may require higher
dosages with higher risks of side effects.1
The viral life cycle encompasses several cru-
cial steps, starting with the attachment of the
virus to the cell and finishing with the release of
the progeny virions from the host cell. SARS-
CoV-2 targets cells through the viral struc-
tural spike protein that binds to an enzyme
on the host cell membranes. Following recep-
tor binding, the virus uses host cell receptors
and endosomes to enter cells. Once inside, vi-
ral polyproteins are synthesized that encode for
the replicase-transcriptase complex. The virus
then synthesizes RNA and structural proteins
leading to completion of assembly and release
of viral particles. These viral lifecycle steps
provide potential targets for drug therapy and
most of the drugs currently in clinical trials in-
hibit key components of the infection life-cycle,
such as viral entry into the host cell, viral repli-
cation, and viral RNA synthesis.2 These targets
are localized to particular subcellular compart-
ments, yet current drug design strategies are
focused on general bioavailability and rarely ad-
dress drug delivery to specific tissues or intra-
cellular compartments. Therefore, knowledge
of the permeability of antiviral drugs, with ref-
erence to both viral and mammalian cell com-
partments, is vitally important from both a
pharmacokinetics and drug design standpoint.
In an effort to accelerate translation of
promising drug candidates, as well as elimi-
nate potentially ineffective or even harmful can-
didate, we present a science-based model to
predict the permeation of drug candidates for
SARS-CoV-2 into coronavirus membrane and
mammalian membranes.
Over the past decades many models have been
developed to estimate drugs’ permeability. The
most commonly used ones are the empirical
”rule of five”,3 QSAR (Quantitative Structure-
Activity Relationship)4 and QSPR (Quanti-
tative Structure-Property Relationship) meth-
ods.5 While QSAR/QSPR methods have shown
their efficacy in screening the binding of anti-
viral drugs and targets, the predicted perme-
ability is at best only accurate to an order of
magnitude, mostly due to the incorporation of
too many descriptors that are not related to
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Figure 2: Structural diagram of the coronavirus membrane with the anchored COVID-19 spike
protein. A) Protein colored according to secondary structure (purple for alpha helix, red for beta
sheet, and gray for random coils). In the lipid bilayer, carbon are shown in gray, nitrogen in red,
oxygen in blue, and phosphate in tan; cholesterol is shown uniformly in orange. Hydrogen atoms
omitted for clarity. B) The anchoring region (part of the heptad repeated, the transmembrane
region, and the C-tails) of the spike protein in the membrane. C) The anchoring region of the spike
protein colored by the residue type. Non-polar residues are colored in white, while polar residues
are in green.
the permeation problem, and the strong depen-
dence on the quality of the training sets em-
ployed.6 On the other end of the accuracy spec-
trum, several methods have been proposed over
the years that leverage a physical description of
the passive permeation process, like the inho-
mogeneous solubility diffusion model and state-
transition model.7 These models, that currently
often involve molecular dynamics (MD) simula-
tions, are either computationally too expensive
for a rapid application or suffer from limited ac-
curacy when drugs of various sizes and shapes
or membranes with different lipid profiles are
involved.
To bridge the gap between accuracy and
ease of use, we have recently introduced a
model to predict the rates of passive perme-
ation of molecules and nanoparticles (up to sev-
eral nm) into phosphatidylcholine membranes.8
The Low-Density Area (LDA) model, which can
combine both experimental and computational
data, has shown accuracy equivalent to fully
atomistic MD methods with a much smaller
computational cost. Such a result was achieved
observing that the permeation process of small
compounds is controlled by the formation of
low-density areas on the membrane surface, and
by factorizing the permeation process into inde-
pendent contributions of the membrane thermal
and pressure fluctuations and characteristics of
the molecules (size, shape and lipophilicity).
Leveraging the LDA model, here we report on
the permeation kinetics of promising drugs can-
didates through coronavirus membranes, with
the overarching goal of providing inputs to
help the design and selection of new or repur-
posed drugs. Additionally, since the target of
many drugs are located inside mammalian cells,
we also report on the permeation kinetics of
the same drugs through five mammalian mem-
branes. A schematic of the overall approach
and data sources used in this study is shown in
Fig. 1. The computations were obtained using a
combination of molecular dynamics simulations
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in conjunction with an augmented LDA model
for membranes. Seventy-nine drugs for SARS-
CoV-2 were analyzed, that comprise FDA ap-
proved drugs, compounds in clinical trials, and
preclinical compounds.2 The computational re-
sults are compared with data available in the
literature on bioavailability and show the po-
tential of the model to aid in the assessment of
drugs’ permeability into a variety of organelles.
Results and Discussion
Molecular description of coron-
avirus envelope
Coronaviridae is a family of large, enveloped,
positive-stranded RNA viruses. The envelope
is derived from the host Endoplasmic Reticu-
lum (ER) membrane and consists of a lipid bi-
layer, in which structural proteins are anchored.
The surface glycoprotein spike that forms large
protrusions from the virus surface, binds to the
host-cell receptor and mediates viral entry.9,10
Since surface characteristics of the biologi-
cal membranes determine the permeability of
drugs, we developed a model to describe the
anchoring of the spike protein to the lipid bi-
layer. The spike contains three segments: a
large ectodomain, a single-pass transmembrane
anchor, and a short intracellular tail. The
region outside the viral core forms alpha he-
lices where coiled-coil interactions, through hy-
drophobic contact, help stabilize the chains.
The tails near the C-terminal are mostly po-
lar with charged residues that form random
coils inside the viral core (i.e., the cytoplas-
mic side after membrane fusion with the host
cell): interactions between the charged residues
and lipid head groups stabilize the end of the
transmembrane region of the spike protein. A
diagram of a section of the coronavirus enve-
lope composed of lipid bilayer and the anchored
spike protein is shown in Fig. 2.
Based on existing data and estimated sec-
ondary structure,11,12 we determined that the
transmembrane region of the COVID-19 spike
protein is formed by the residues in the #1210-
1235 range. The charge-charge interactions
among residues 1215:TYR, 1219:GLY, and
1223:GLY contribute to hold the three chains
together inside the hydrophobic region of the
membrane lipids. The density of the spike pro-
tein, used in our simulations, reflects the ex-
perimental density of about 100 nm2 to 200 nm2
per transmembrane proteins (of any kind), es-
timated from a viral envelop diameter of 80 nm
to 120 nm13 and an approximate number of 800
transmembrane proteins per virion.14 To reduce
the computational cost, after the initial equili-
bration run used to validate the stability of the
protein anchoring region, we considered only
part of the protein (Fig. 2B and C) as the rest of
the spike protein is far enough (5 nm or more) to
affect the formation and life time of low-density
areas on the viral membrane surface.
For the lipid bilayer, slightly higher concen-
trations of sphingomyelin and phosphatidyli-
nositol were found in the viral envelope, com-
pared to the ER membrane from where coron-
aviruses acquire their membrane envelope.15
Drugs’ Membrane Permeability
Figure 3: Ratios of times of entry for drugs in
different membranes. The time of entry in ER
membrane is chosen as reference.
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Figure 4: Times of permeation for drugs candidates in different organelle membranes, grouped
by A) viral baits, B) related mammalian processes when viral baits were unknown. Error bars
represent one standard deviation. Tabulated data in the supplementary materials.
The LDA model describes the permeation as
a gated entry process, regulated by the chance
of the molecule to find a low-density area on
the membrane surface and by the solubility of
the drug in the hydrophobic phase. The four
parameters used in the model separate the con-
tributions of the characteristics of the molecules
(size, shape, solubility) from the properties of
the membranes (lipid density distribution).
In addition to the viral envelope described be-
fore (with and without spike protein), we stud-
ied the surface properties of five membranes
corresponding to various mammalian compart-
ments (lysosome, plasma, Golgi, mitochondrial
and endoplasmic reticulum membranes) using
all-atom molecular dynamics simulations.
Fig. 3 reports the distribution of the perme-
ation times of the 79 drugs in all the membranes
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relative to the ER membrane, which was cho-
sen as reference since the permeation in this
membrane is the fastest for all drugs. The re-
sults show that the inclusion of the transmem-
brane protein in the COVID-19 membrane has
a large impact on drug’s membrane permeabil-
ity. The presence of the transmembrane protein
affects the frequency, shape, and lifetime of low-
density areas in the LDA model. Indeed, when
comparing the distribution of permeation times
for ER and coronavirus membrane, with and
without the spike protein, we observe a ∼40%
increase in the permeation time due to the pres-
ence of proteins and ∼10% due to the change in
lipid composition. This effect is mostly due to
the reduced mobility of the lipids near a rigid
object similar to what has been observed for
C60 fullerenes in lipid bilayers.
16
While the presence of the spike protein in the
COVID-19 membrane results in an increased
stiffness, the viral membrane is still generally
two times more permeable than plasma mem-
brane and lysosomes (before accessible surface
and concentration effects are considered). Al-
though currently very few drugs are required
to permeate through viral membranes, this dif-
ference can potentially be exploited by other
classes of compounds, like nanoparticles, which
can amplify the effect of membrane stiffness due
to their relative large size. The individual times
of permeation of drug candidates grouped by
viral baits or, when that is unknown, by bi-
ological processes, are shown in Fig. 4. The
results show a variety of timescales going from
nanoseconds to microseconds depending on the
drug and membrane.
Albeit the bioavailability of a drug is af-
fected by many factors, like metabolism rate
and plasma protein binding,17 we find a nega-
tive correlation between the bioavailability of
drugs and the permeation time predicted by
the LDA model. For example, for drugs within
the same group, Lisinopril (Fig. 4B, Cell En-
try) is the least permeable compound as well
as the compound with the lowest bioavailabil-
ity (25% based on experimental data18). On
the other hand, Captopril, Nafamostat, and
Camostat, for which we predict permeation
times that are one order of magnitude shorter
than Lisinopril, have an estimated bioavail-
ability of 100% 1. Similar observations can
be made for Rapamycin (Fig. 4A, N), which
has lower bioavailability than Sapanisertib and
Silmitasertib. While undeniably other factors
affect the ability of a drug to reach the intended
target, these results show how useful membrane
permeability predictions can be.
Interestingly, the permeation times of drugs
that are currently identified as most promising
candidates against COVID-19 during their clin-
ical trial19 are among the shortest compared to
other drugs with similar targets. For example,
drugs related to the disruption of viral transla-
tion such as Ternatin-420 (Fig. 4B Translation),
Zotatifin21 (Fig. 4A, Nsp2) and Plitidepsin22
(Fig. 4B, Translation), and sigma receptors
such as Haloperidol23 and Compound PB2824
(Fig. 4A Nsp6 and Orf9c), Melperone, Clop-
erastine,25 and Clemastine (Fig. 4B, Protein
Processing), and the female hormone proges-
terone (Fig. 4B, Viral transcription) are among
the most permeable compounds in their re-
spective categories. While a direct comparison
among these drugs is not straightforward, as
they need to cross different membranes in or-
der to reach their intended target, the time of
permeation in their least permeable membrane
(i.e., lysosome or plasma) is 40 ns on average
with an upper bound of 62 ns, while the re-
maining drugs require an average of 242 ns and
a maximum of 4.6 µs.
Conclusion
In this paper, we present a model to compute
the permeability of drugs that target various
steps in the lifecycle of infection of SARS-CoV-
2. The model is based on the LDA theory de-
veloped by our group that describes the per-
meation process as regulated by low-density
area on the membrane surface and solubility of
drugs in the hydrophobic phase of the mem-
brane itself. Starting from the virus structure,
we developed an atomistic model of the spike
protein anchored to the lipid bilayer to study
the viral envelope. Molecular dynamics simu-
1data from http://drugbank.ca
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lations of the viral and five mammalian mem-
branes were carried out to determine the dy-
namics and characteristics of the membranes.
The computational results were compared with
data present in the literature on bioavailability,
and show that the LDA model can be applied
to predict the permeability of drugs through
various membranes and to gain insights on the
differences between membranes and potentially
organs or organisms. From a drug design, as
well as health assessment perspective, this pre-
dictive capability can facilitate compound eval-
uation by ruling out candidates with low perme-
ability or excessive permeability in unintended
organs or organelles. Indeed, the LDA model
can be used to estimate the absorption selectiv-
ity of different targets (e.g., carcinogenic cells,
organs) by molecules and nanoparticles without
need of large set of preexisting data, making it
an invaluable tool for the comprehensive and
fast validation pipeline of new compounds.
While the results reported in this paper fo-
cus on drugs for SARS-CoV-2, the method is
general and flexible and can be employed, with
other tools to shorten the effective response
time to a global pandemic. Our work provides
a means for scientific discovery to move closer
to the speed of pandemic spreads and it can be
generalized to future events.
Methods
Membrane simulations
We used NAMD26 version 2.13 with CHARMM
Force Field27 version 36 for lipids, and TIP3P28
for water molecules. All MD simulations were
performed with a timestep of 2 fs while keep-
ing all the C–H and O–H bonds rigid via
the SHAKE algorithm.29 Long range electro-
static interactions were modeled with the par-
ticle mesh Ewald method30 using a 0.1 nm grid
spacing, a tolerance of 10−6 and cubic inter-
polation; cubic periodic boundary conditions
were applied. Temperature was kept constant
at 310 K using a Langevin thermostat31 with a
time constant of 1 ps, while pressure was kept at
101.325 kPa using Langevin piston method32,33
with period of 50 fs and 25 fs decay. To account
for the intrinsic anisotropy of the system, the
production simulations were performed in the
NPsT ensemble, where the x and y dimensions
of the periodic system (coplanar with the mem-
brane) are allowed to vary independently from
the z dimension. Non-bonded short-range inter-
actions where smoothly switched to 0 between
1 and 1.2 nm with a X-PLOR switch function.
The lipid compositions for cellular organelles
(plasma, lysosome, Golgi, mitochondrial) were
taken from Horvath et al.,34 and the ER and
viral membrane from van Genderen et al.15 Ta-
ble S1 provides more details about the compo-
sition of each membrane. Membranes without
spike proteins had an approximate size of 8 nm
by 8 nm, subject to round up to satisfy the re-
quired imposed by the lipid composition. The
membranes with spike proteins were extended
to guarantee at least 4 nm of separation between
the closest atom of the spike protein with its
nearest periodic image, resulting in membranes
of approximately 15.4 nm by 15.4 nm for the
system with the entire protein and 9.5 nm by
9.5 nm for the system with the anchoring region
only. System were simulated in explicit solvent
to guarantee at least 6 nm of separation between
the membrane or protein and their periodic im-
age from top and bottom. The lipids, protein,
water molecules and ions were initially placed
by the CHARMM-GUI membrane builder.35
Each membrane was equilibrated for at least
30 ns in the NPsT ensemble described above.
The membranes were assumed to be at equilib-
rium once the time average of the area per lipid
in a NPsT simulations was varying less than
10% in 10 ns. The surface properties (LDAs)
were then obtained by running a additional
100 ns.
Spike protein in membrane
The main structure (residues 27 to 1146) of the
spike protein can be found in the protein data
bank #6VSB, based on the cryo-EM structure
of Wrapp et al.11 The secondary structure of
residue 1146 to 1273 was instead based on the
prediction of the C-I-TASSER model.12 The
secondary structure of the alpha helices of the
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lower chunk was left unmodified, while the ran-
dom coils were twisted to align the alpha helices
perpendicularly to the membrane. Simulations
of 30 ns show that the anchor is stable with no
lipid rearrangement or vertical translation rel-
ative to the membrane.
Drug properties
To better factor the drugs’ flexibility in the
model, their size/shape was estimated by con-
sidering a large sample of conformations at
room temperature in water. For this purpose,
we run molecular dynamics simulations using
the CHARMM General Force Field36 to model
the atomic forces and collected the molecule’s
conformations every 20 ps. CGenFF37 software
was used to assist in the production of the
needed topology files. Each drug molecule was
presented at the center of an cubic box of 6 nm
in each dimension, containing explicit solvent
of water and 0.15 M NaCl.
MD setup for drug simulation was the same
as the membrane simulations, except the use of
an isotropic ensemble (NPT). Each system was
minimized for 1000 steps, following 0.5 ns of re-
laxation and 0.5 ns of production. Every 20 ps
the molecule shape was estimated using the pro-
tocol described previously8 and then used to
calculate the PLDA for the specific conforma-
tion. The final value for PLDA was computed
by averaging over the values obtained for all
the conformations. Finally, the partition coef-
ficients of the drugs molecules in octanol and
water were taken from PubChem website using
experimental values when available, or predic-
tion from XLogP3 model38 otherwise.
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